Novartis pipeline setback adds second in a week, Market Talk says
Novartis suffered a second major pipeline setback in a week after acquired drug candidate del-desiran failed in a late-stage study, according to a Vontobel research note cited by Stefan Schneider.
Novartis just suffered its second major pipeline setback in the past week after a drug candidate it acquired through its recent $12 billion Avidity Biosciences deal failed in a late-stage study, Vontobel's Stefan Schneider says in a research note. News that experimental drug del-desiran missed the…